Delivery Order SPE2DR25D1109-SPE2DR26FFF5N
- Not listed
- The Defense Logistics Agency (DLA) awarded a $2,681.68 delivery order to AmerisourceBergen Drug Corp on September 11, 2025, for the supply of Lisdexamfetamine 30 mg capsules in quantities of 100 units. This is a firm fixed price contract with an ultimate completion date of September 12, 2025, and represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical. The contract was competitively awarded with no set-aside designation and will...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 23, 2025, for the supply of Lisdexamfetamine 60 mg capsules (90-count units) valued at $2,794.14 under a firm fixed-price contract type. This non-set-aside award represents a child delivery order executed against AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 prime vendor agreement running through December 2026. The product will...
- The Defense Logistics Agency awarded a $10,066.22 delivery order to AmerisourceBergen Drug Corp on September 18, 2025, for the supply of Lisdexamfetamine 20 mg capsules (90-count units). This is a firm fixed-price delivery order with an ultimate completion date of September 19, 2025, and represents a non-competitive set-aside contract. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains its primary...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 30 mg capsules (100-count units) under a firm fixed-price contract valued at $2,646.20. The contract was awarded on August 25, 2025, with an ultimate completion date of August 26, 2025, and carries no set-aside designation, indicating it was competitively awarded. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC)...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for Lisdexamfetamine 30 mg capsules (100-count units) on September 3, 2025, with a ceiling value of $1,176.88 and ultimate completion date of September 4, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract represents a child award under a larger...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,883.72 for Lisdexamfetamine 30 mg capsules (100-count units) on July 30, 2025, with an ultimate completion date of July 31, 2025. This firm fixed-price contract represents a non-set-aside, competitively awarded delivery order under the company's broader pharmaceutical supply arrangements with DLA. The product will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania, where the...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 18, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100-count units) under a firm fixed-price contract with a ceiling value of $1,137.22. This non-set-aside delivery order is scheduled for ultimate completion on August 19, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role...
- The Defense Logistics Agency (DLA) awarded AmerisourceBergen Drug Corp a delivery order valued at $3,897.96 for Lisdexamfetamine 70 mg capsules (100-count units) on September 26, 2025, with an ultimate completion date of September 29, 2025. This firm fixed-price delivery order was competitively awarded with no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award is issued under the company's existing Indefinite...
- The Defense Logistics Agency awarded a $3,672.67 delivery order to AmerisourceBergen Drug Corp on October 21, 2025, for the supply of Lisdexamfetamine 40 mg capsules (100-count units). This is a firm fixed-price contract with an ultimate completion date of October 22, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award was made through open competition with no set-aside designation. This delivery order represents a child contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 40 mg capsules (100 count) valued at $10,977.83. The contract, awarded on September 4, 2025, with an ultimate completion date of September 5, 2025, utilizes firm fixed pricing with no set-aside designation. Performance will be conducted from the contractor's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under...
- SPE2DR25D1109Indefinite Delivery Contract
- SPE2DR25D1109-SPE2DR26FFF5NDelivery Order
The Defense Logistics Agency awarded a delivery order contract valued at $2,586.18 to AmerisourceBergen Drug Corp for the supply of Lisdexamfetamine 70 mg capsules in quantities of 100 units. This competitive, non-set-aside award with firm fixed pricing was issued on October 24, 2025, with an ultimate completion date of October 27, 2025. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a comprehensive pharmaceutical supply vehicle valued at $999,999,999.00 and extending through December 2026. As a prime contractor for the DLA Medical Supply Chain, AmerisourceBergen serves as a critical vendor supplying pharmaceuticals and medical supplies across multiple therapeutic domains to support military and veteran healthcare systems globally. The delivery order for Lisdexamfetamine—a controlled substance stimulant medication used to treat attention-deficit/hyperactivity disorder—represents a routine procurement of specialty medications through this established federal pharmacy vendor relationship.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.6k | 10/24/25 |